Viridian inks commercial manufacturing deal with WuXi Biologics for veligrotug

Viridian Therapeutics, Inc.\DE

Agreement covers long-term supply of veligrotug drug substance and drug product, if approved.
WuXi Biologics is non-exclusive supplier; Viridian may use alternate manufacturers.
Initial term of 5 years, auto-renewing for successive 5-year periods unless 24-month non-renewal notice given.
Volume-based pricing fixed through Dec 31, 2026, then annually adjustable; pass-through costs reimbursed.
Company may terminate on 30 days' notice for change in law materially impacting WuXi's performance.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Viridian Therapeutics, Inc.\DE entered into Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited (effective 2026-05-24).

Action: entry
Agreement: supply
Counterparty: WuXi Biologics (Hong Kong) Limited
Effective: 2026-05-24

Exact text from the filing

On May 24, 2026, Viridian Therapeutics, Inc. (the “Company”) entered into a Commercial Manufacturing Services Agreement (the “Agreement”) with WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”) pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for commercial use (the “Product”), if approved.

View on SEC.gov

235 material agreements filed in the last 30 days. Browse all material agreements →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-26-239246

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.